These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38689620)

  • 1. Navigating the challenges: a case report on managing a complicated postpartum course in type 3 von Willebrand disease with alloantibodies.
    van der Zwet K; van Galen KPM; Evers ACC; Fischer K; Schutgens REG; van Vulpen LFD
    Res Pract Thromb Haemost; 2024 Mar; 8(3):102399. PubMed ID: 38689620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature.
    Shanmukhaiah C; Jijina F; Kannan S; Pai NG; Kulkarni B; Khuba SV; Shaikh M; Joshi A; Phatale R; Apte S
    Haemophilia; 2022 Mar; 28(2):286-291. PubMed ID: 35014121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review.
    Giuffrida AC; Siboni SM; Baronciani L; Poli G; Gandini G; Peyvandi F
    Semin Thromb Hemost; 2024 Jun; ():. PubMed ID: 38936417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Haemophilia; 2021 Mar; 27(2):e194-e203. PubMed ID: 33555083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease.
    Yaoi H; Shida Y; Ogiwara K; Kitazawa T; Shima M; Nogami K
    Haemophilia; 2022 Sep; 28(5):694-701. PubMed ID: 35478475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
    Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
    J Cardiothorac Vasc Anesth; 2022 Mar; 36(3):724-727. PubMed ID: 33618961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro.
    Bravo MI; Raventós A; Pérez A; Costa M; Willis T
    J Thromb Haemost; 2020 Aug; 18(8):1934-1939. PubMed ID: 32379931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature.
    Thomas VM; Abou-Ismail MY; Lim MY
    Haemophilia; 2022 Jan; 28(1):4-17. PubMed ID: 34820989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of emicizumab prophylaxis in severe von Willebrand disease.
    Barg AA; Avishai E; Budnik I; Brutman TB; Tamarin I; Dardik R; Bashari D; Misgav M; Lubetsky A; Lalezari S; Livnat T; Kenet G
    Blood Cells Mol Dis; 2021 Mar; 87():102530. PubMed ID: 33341070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy and delivery in women with von Willebrand disease.
    Castaman G; James PD
    Eur J Haematol; 2019 Aug; 103(2):73-79. PubMed ID: 31107984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of emicizumab therapy in two adult patients with type 3 von Willebrand disease.
    LeMaistre FI; Chiang E; Streiff MB; Yui JC
    Blood Coagul Fibrinolysis; 2024 Jun; 35(4):206-208. PubMed ID: 38625829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report.
    Chikasawa Y; Hagiwara T; Bingo M; Amano K; Kikuchi S; Mitsuhashi A; Shinozawa K; Fukutake K; Kinai E
    Int J Hematol; 2022 Oct; 116(4):622-629. PubMed ID: 35532874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis.
    James AH; Konkle BA; Kouides P; Ragni MV; Thames B; Gupta S; Sood S; Fletcher SK; Philipp CS
    Haemophilia; 2015 Jan; 21(1):81-7. PubMed ID: 25333737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.
    Atiq F; Schütte LM; Looijen AEM; Boender J; Cnossen MH; Eikenboom J; de Maat MPM; Kruip MJHA; Leebeek FWG
    Blood Adv; 2019 Dec; 3(24):4147-4154. PubMed ID: 31834934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of von Willebrand disease.
    Rodeghiero F; Castaman G
    Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.